Back to top
more

Option Care Health (OPCH)

(Delayed Data from NSDQ)

$28.26 USD

28.26
1,842,798

-1.09 (-3.71%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $28.26 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (62 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Option Care (OPCH) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Option Care (OPCH) delivered earnings and revenue surprises of +2.50% and +4.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

BTSG vs. OPCH: Which Home Infusion Stock is a Better Buy Now?

by Urmimala Biswas

BTSG surges with 33% infusion growth and stronger EPS gains, making it a more compelling pick than OPCH right now.

Sridatri Sarkar headshot

Can BrightSpring's Q1 Strength Carry Through 2025 Headwinds?

by Sridatri Sarkar

BTSG faces margin pressure, but strong first-quarter gains in Pharmacy Solution and Provider Services lift confidence.

Urmimala Biswas headshot

BrightSpring Soars to All-Time High on Quality Strength: Still a Buy?

by Urmimala Biswas

BTSG stock hits an all-time high with a 120% gain as soaring quality ratings and strong Q1 results fuel investor confidence.

Zacks Equity Research

Option Care (OPCH) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Option Care (OPCH) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

OPCH vs. CHE: Which Stock Is the Better Value Option?

by Zacks Equity Research

OPCH vs. CHE: Which Stock Is the Better Value Option?

Zacks Equity Research

Option Care (OPCH) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Option Care (OPCH) delivered earnings and revenue surprises of 11.11% and 5.38%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

HCA Healthcare Q1 Earnings Beat on Growing Patient Volumes

by Zacks Equity Research

HCA continues to witness growth in reported and same-facility admissions. The company reaffirms 2025 guidance.

Zacks Equity Research

Best Growth Stocks to Buy for April 25th

by Zacks Equity Research

COMM, OPCH and BGC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on April 25, 2025

Zacks Equity Research

Molina Healthcare Q1 Earnings Beat Estimates on Growing Premiums

by Zacks Equity Research

MOH continues to expect 2025 premium revenues to be around $42 billion.

Zacks Equity Research

Best Growth Stocks to Buy for April 24th

by Zacks Equity Research

OPCH, COMM, and JD it to the Zacks Rank #1 (Strong Buy) growth stocks list on April 24, 2025.

Zacks Equity Research

Elevance Health's Q1 Earnings Beat Estimates on Rising Premiums

by Zacks Equity Research

ELV continues to witness significant growth in Q1 revenues. However, its operating costs surge.

Zacks Equity Research

Best Growth Stocks to Buy for April 22nd

by Zacks Equity Research

OPCH, COMM, and JD it to the Zacks Rank #1 (Strong Buy) growth stocks list on April 22, 2025.

Zacks Equity Research

UnitedHealth Lags Q1 Earnings & Revenues, Slashes Estimates

by Zacks Equity Research

UNH continues to witness significant growth in medical costs. However, its operating cost ratio improves.

Zacks Equity Research

Best Growth Stocks to Buy for April 17th

by Zacks Equity Research

OPCH, COMM and JD made it to the Zacks Rank #1 (Strong Buy) growth stocks list on April 17, 2025.

Zacks Equity Research

CYH to Sell Stake in Cedar Park Regional to Ascension in $460M Deal

by Zacks Equity Research

Community Health is set to divest an 80% ownership stake in Cedar Park Regional to Ascension Health.

Zacks Equity Research

Best Growth Stocks to Buy for April 15th

by Zacks Equity Research

OPCH, COMM and JD made it to the Zacks Rank #1 (Strong Buy) growth stocks list on April 15, 2025.

Zacks Equity Research

OPCH or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

OPCH vs. CHE: Which Stock Is the Better Value Option?

Zacks Equity Research

Centene Extends SilverSummit's Presence to the Edges of Nevada

by Zacks Equity Research

CNC's subsidiary, SilverSummit, secures a five-year Nevada Medicaid contract, reinforcing its foothold in managed care in rural and frontier areas.

Zacks Equity Research

Zacks Industry Outlook Highlights DaVita, Encompass Health, Option Care Health and Addus HomeCare

by Zacks Equity Research

DaVita, Encompass Health, Option Care Health and Addus HomeCare have been highlighted in this Industry Outlook article.

Debanjana Dey headshot

4 Stocks to Watch in a Dynamic Outpatient Home Health Industry

by Debanjana Dey

An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DVA, EHC, OPCH and ADUS are well-poised to gain.

Zacks Equity Research

Best Growth Stocks to Buy for April 9th

by Zacks Equity Research

PBI, MPTI and OPCH made it to the Zacks Rank #1 (Strong Buy) growth stocks list on April 9, 2025

Zacks Equity Research

Ensign Group Invests in Growth With New Facility Acquisitions

by Zacks Equity Research

ENSG continues its strategic growth with new acquisitions across Washington and California.

Zacks Equity Research

Best Growth Stocks to Buy for April 3rd

by Zacks Equity Research

COMM, OPCH, and JD it to the Zacks Rank #1 (Strong Buy) growth stocks list on April 3, 2025.

Zacks Equity Research

Best Growth Stocks to Buy for April 1st

by Zacks Equity Research

COMM, OPCH, and JD it to the Zacks Rank #1 (Strong Buy) growth stocks list on April 1, 2025.